To expand the potential conformational space available to the polypyrroline structural motif, an open chain, D,L-alternating hexapyrrolinone was designed and synthesized. Structural studies, including solution NMR and X-Ray crystallographic analysis, revealed that the hexapyrrolinone adopts a turn conformation both in solution and in the solid state, with aggregation in solution and a nanotube-like quaternary structure in the crystal.A major achievement in the field of non-peptide peptidomimetics would comprise the design and synthesis of biologically relevant mimics, capable of adopting conformations similar to the three principal secondary structures accessible to peptides and proteins (e.g., β-turns, β-strands, or α-helices), with conformational control manifest simply via structural modification of the side-chains and/or the stereogenicity of the constituent monomers. To date, only a limited number of conformationally versatile nonpeptide peptidomimetics have been reported.1In 1992, the Hirschmann-Smith collaboration reported the design and synthesis of a new class of peptidomimetics based on the pyrrolinone scaffold ( Figure 1).2 Computational studies suggested that oligomers based on this repeating vinylogous amide motif held the promise of adopting structures similar, but not identical to, the three secondary structures of peptides and proteins.2 , 3 As such, the polypyrrolinones constituted early examples of foldamers as defined by Gellman,4 , 1a,b and elegantly demonstrated for β-peptides both by Seebach5 , 1c and Gellman.4b , 1a,b Pleasingly, initial studies demonstrated that homochiral polypyrrolinones (e.g., all D),6 such as (−)-1, can adopt extended parallel (1a , Figure 1) or antiparallel (1b) β-strand/sheet mimics, depending on the presence or absence of a Boc Cterminus.2 , 3 , 7 This observation led to the design and synthesis of a series of potent pyrrolinone-based enzyme inhibitors,8 requiring the β-strand/-sheet motif, including metalloproteases,9 and orally bioavailable HIV-1 protease inhibitors,10 as well as a peptidepyrrolinone hybrid ligand for the class II MHC protein HLA-DR1.11